wada prohibited list growth hormone releasing peptides ipamorelin cjc-1295 Identification of CJC‐1295, a growth‐hormone‐releasing peptide, in an unknown pharmaceutical preparation - Henninge - 2010 - Drug Testing and Analysis CJC 1295, ipamorelin and retatrutide:

Decrease dose if: Experiencing consistent side effects (headaches, fatigue, GI disturbance), achieving satisfactory results at current dose with no need for escalation, or cost considerations favor using minimum effective dose

Unlike GLP-1 agonists, the changes are compositional rather than scale-weight driven: patients may not lose significant total body weight but will show meaningful reduction in waist circumference and visceral fat volume

Because peptides can influence immune system signaling, individuals with autoimmune disorders or compromised immune function should consult a healthcare professional before treatment

2001;86(1):E18-E22